Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Mar 21;373(9668):1033-40.
doi: 10.1016/S0140-6736(09)60251-8.

Monoclonal antibodies for cancer immunotherapy

Louis M Weiner  1 , Madhav V Dhodapkar, Soldano Ferrone
Affiliations
Review

Monoclonal antibodies for cancer immunotherapy

Louis M Weiner et al. Lancet. .

Abstract

Monoclonal antibodies are effective treatments for many malignant diseases. However, the ability of antibodies to initiate tumour-antigen-specific immune responses has received less attention than have other mechanisms of antibody action. We describe the rationale and evidence for the development of antibodies that can stimulate host tumour-antigen-specific immune responses. Such responses can be induced through the induction of antibody-dependent cellular cytotoxicity, promotion of antibody-targeted cross-presentation of tumour antigens, or by triggering of the idiotypic network. Future treatment modifications or combinations might be able to prolong, amplify, and shape these immune responses to increase the clinical benefits of antibody therapy for human cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1. A proposed model for the induction of adaptive immune responses by ADCC
An anti-tumor monoclonal antibody binds to an antigen on a tumor cell, and engages an Fc receptor on a killer cell. This induces antibody-promoted phagocytosis or direct cytolysis, resulting in antigen processing and presentation via MHC Class I or Class II molecules on antigen-presenting cells. This leads to the induction of host anti-tumor immunity manifested by either the production of tumor-directed host cytotoxic T-lymphocytes and/or antibodies.
Figure 2
Figure 2. Fc receptors and immune balance
Signaling via Fcγ receptors (FcγR) is regulated by a balance of activating versus inhibitory FcγR, which carry immune tyrosine activating motif (ITAM) versus immune tyrosine inhibitory motifs (ITIM). Fc domains of monoclonal antibodies can generally engage both forms of receptors. The balance of net engagement of activating versus inhibitory receptors depends on both host and antibody related factors and determine antibody mediated activation of immunity.
Figure 3
Figure 3. Triggering of the idiotypic network by immunization with a tumor antigen
The antibody, referred to as Ab1, elicited by a tumor antigen induces anti-idiotypic antibodies to the idiotopes expressed on its variable region. Some anti-idiotypic antibodies, referred to as Ab2β, react with the area of the Ab1 variable region, which binds to the nominal antigen. These anti-idiotypic antibodies bear the internal image of the nominal antigen and therefore can induce tumor antigen binding antibodies, referred to as Ab3. Other anti-idiotypic antibodies, referred to as Ab2γ, react with areas of the Ab1 variable region, which do not bind to the nominal antigen. They can interfere with the binding of Ab1 to the nominal antigen, and induce anti-anti-idiotypic antibodies which do not bind to the nominal antigen. Other anti-idiotypic antibodies, referred to as Ab2α, react with areas of the Ab1 variable region outside its antigen combining site. They do not interfere with the binding of Ab1 to the nominal antigen, and induce anti-anti-idiotypic antibodies which do not bind to the nominal antigen.
Figure 4
Figure 4. Molecular basis of tumor antigen mimicry by an anti-idiotypic antibody
The mimicry of a tumor antigen by an anti-idiotypic antibody may reflect the homology of an amino acid sequence stretch of a tumor antigen with a stretch of the anti-idiotypic antibody variable region amino acid sequence or conformational similarity between a tumor antigen determinant and an anti-idiotypic antibody idiotope.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–33. - PubMed
    1. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259–66. - PubMed
    1. Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin’s lymphoma. Semin Oncol. 2002;29(2 Suppl 6):18–22. - PubMed
    1. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2003;20:2453–63. - PubMed
    1. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93:3678–84. - PubMed

MeSH terms